https://www.pharmanow.live/latest-news/biological-e-appoints-v-krishnakumar-ceo-biopharma-cdmo 2026-10-03T13:43:23+05:30 Pharma Now en 2026-10-03T00:00:00+05:30 Biological E Appoints V Krishnakumar CEO Of Global Biopharma CDMO Biological E https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/6ac409e4-9c3f-43f0-8630-9d4a57ff0cdb/768e568c-f325-4ab4-83c1-4016f8df73cc.png https://www.pharmanow.live/latest-news/zydus-lifesciences-extends-sunshine-healthcare-lanka-jv-deadline-december-2026 2026-10-03T13:44:22+05:30 Pharma Now en 2026-10-03T00:00:00+05:30 Zydus Extends Sunshine Healthcare JV Timeline To December 2026 Zydus https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/6ac409e4-9c3f-43f0-8630-9d4a57ff0cdb/9fa0e768-4ca7-4c8d-a69d-599c169c0178.png https://www.pharmanow.live/latest-news/godavari-biorefineries-secures-mexican-patent-antiviral-compounds 2026-10-03T13:46:49+05:30 Pharma Now en 2026-10-03T00:00:00+05:30 Godavari Biorefineries Secures Mexican Antiviral Patent Godavari https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/6ac409e4-9c3f-43f0-8630-9d4a57ff0cdb/538cf8f1-9dac-4602-899d-33deee0307d0.png https://www.pharmanow.live/latest-news/bayer-2-2-billion-us-manufacturing-site-reshoring 2026-10-03T14:20:33+05:30 Pharma Now en 2026-10-03T00:00:00+05:30 Bayer Commits $2.2 Billion To New U.S. Sites Amid Reshoring Drive Bayer https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/bayer-2-2-billion-us-manufacturing-site-reshoring-202620261003142026.webp https://www.pharmanow.live/latest-news/novo-nordisk-denecimig-bla-review-extended-fda-facility-remediation 2026-10-03T14:12:22+05:30 Pharma Now en 2026-10-03T00:00:00+05:30 FDA Plant Inspection Delays Novo Nordisk Denecimig BLA Review Now FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/novo-nordisk-denecimig-bla-review-extended-fda-facility-remediation-202620261003141211.webp https://www.pharmanow.live/latest-news/eli-lilly-fda-approval-pirtobrutinib-first-line-cll-sll 2026-10-03T13:13:19+05:30 Pharma Now en 2026-10-03T00:00:00+05:30 FDA Approves Lilly Pirtobrutinib For First Line CLL SLL Patients FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/eli-lilly-fda-approval-pirtobrutinib-first-line-cll-sll-202620261003131309.webp https://www.pharmanow.live/latest-news/fda-updates-hctp-non-blood-biologics-deviation-reporting-codes-october-2026 2026-10-03T13:09:39+05:30 Pharma Now en 2026-10-03T00:00:00+05:30 FDA Updates Deviation Codes For Biologics Effective October 2026 FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-hctp-non-blood-biologics-deviation-reporting-codes-october-202620261003130936.webp https://www.pharmanow.live/latest-news/fda-updates-biological-product-deviation-reporting-blood-product-codes-october-2026 2026-10-03T13:04:58+05:30 Pharma Now en 2026-10-03T00:00:00+05:30 FDA Updates Blood Product Deviation Codes Effective October 2026 FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-biological-product-deviation-reporting-blood-product-codes-october-202620261003130446.webp https://www.pharmanow.live/latest-news/abbvie-hrsa-340b-rebate-model-pilot-imbruvica-linzess-vraylar-2027 2026-10-03T12:59:38+05:30 Pharma Now en 2026-10-03T00:00:00+05:30 AbbVie Joins HRSA 340B Rebate Pilot For Three Drugs January 2027 AbbVie https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/abbvie-hrsa-340b-rebate-model-pilot-imbruvica-linzess-vraylar-202720261003125925.webp https://www.pharmanow.live/latest-news/fda-transparency-roadmap-complete-response-letters-fy27-priorities 2026-10-03T12:52:37+05:30 Pharma Now en 2026-10-03T00:00:00+05:30 FDA Releases Transparency Roadmap With Complete Response Letters Now FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-transparency-roadmap-complete-response-letters-fy27-priorities-202620261003125137.webp https://www.pharmanow.live/latest-news/lilly-oral-glp1-diabetes-heart-disease-risk-reduction-solid-dosage-scale-up 2026-10-03T11:49:44+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 Lilly Achieves Oral GLP-1 Risk Reduction Data Signaling Solid Dosage Scale-Up Demand Lilly https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/lilly-oral-glp1-diabetes-heart-disease-risk-reduction-solid-dosage-scale-up-202620261003114925.webp https://www.pharmanow.live/latest-news/tapi-appoints-serge-rogasik-ceo-global-api-cdmo-expansion 2026-10-03T11:45:54+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 TAPI Appoints Serge Rogasik as CEO to Drive Global API and CDMO Expansion TAPI Appoints Serge Rogasik https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/tapi-serge-rogasik-ceo-global-api-cdmo-expansion-202620261003114548.webp https://www.pharmanow.live/latest-news/roche-faricimab-vabysmo-real-world-durability-retinal-disease-data 2026-10-03T11:43:15+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 Roche Real-World Data Confirm Faricimab Durability Across Multiple Retinal Disease Indications Roche https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/roche-faricimab-vabysmo-real-world-durability-retinal-disease-data-202620261003114149.webp https://www.pharmanow.live/latest-news/roche-giredestrant-phase3-pfs-benefit-er-positive-breast-cancer 2026-10-03T11:37:02+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 Roche Achieves Significant PFS Benefit with Giredestrant in Phase 3 ER+/HER2- Breast Cancer Trial Roche https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/roche-giredestrant-phase-3-pfs-benefit-er-positive-breast-cancer-202620261003113700.webp https://www.pharmanow.live/latest-news/teva-ecopipam-phase3-ole-data-fda-priority-review-pediatric-tourette-syndrome 2026-10-03T11:33:42+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 Teva Presents Ecopipam Phase 3 and OLE Data Supporting FDA Priority Review for Pediatric Tourette Syndrome Teva https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/teva-ecopipam-phase-3-ole-data-fda-priority-review-pediatric-tourette-syndrome-202620261003113250.webp https://www.pharmanow.live/latest-news/teva-ecopipam-d1-receptor-tourette-syndrome-pediatric-journal-child-neurology 2026-10-03T11:15:51+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 Teva Gains Journal Validation for Ecopipam's First-in-Class D1 Mechanism in Pediatric Tourette Syndrome Teva https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/teva-ecopipam-d1-receptor-tourette-syndrome-pediatric-neurology-202620261003111538.webp https://www.pharmanow.live/latest-news/fda-ich-m15-webinar-model-informed-drug-development-october-2026 2026-10-03T12:43:42+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 FDA Hosts ICH M15 Webinar to Clarify Model-Informed Drug Development Submission Standards on October 29 ICH M15 https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-ich-m15-webinar-model-informed-drug-development-october-202620261003111234.webp https://www.pharmanow.live/latest-news/bristol-myers-squibb-fda-pediatric-approval-camzyos-obstructive-hypertrophic-cardiomyopathy 2026-10-03T10:59:40+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 Bristol Myers Squibb Gains FDA Pediatric Approval for Camzyos in Obstructive Hypertrophic Cardiomyopathy FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/bristol-myers-squibb-fda-pediatric-approval-camzyos-obstructive-hypertrophic-cardiomyopathy-202620261003105926.webp https://www.pharmanow.live/latest-news/bespak-nasadose-ultra-soft-spray 2026-10-02T18:08:43+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 Bespak Expands Nasal Drug Delivery Portfolio with NasaDose Ultra NasaDose Ultra, Bespak, NasaDose Ultra Soft Unit Dose Spray, Resyca, Upperton, nasal drug delivery, soft mist technology, unit dose nasal spray, nose-to-brain delivery https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/bespak-nasadose-ultra-soft-unit-dose20261002180347.webp https://www.pharmanow.live/latest-news/pharma-nows-inside-cdmo-behind-the-glass-goes-inside-drug-delivery-engineering-with-phillips-medisizes-justin-westendorf 2026-10-02T20:12:15+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 Pharma Now's "Inside CDMO: Behind the Glass" Goes Inside Drug-Delivery Engineering with Phillips Medisize's Justin Westendorf Inside CDMO podcast, Justin Westendorf Phillips-Medisize, drug-delivery device design, Pharma Now CDMO series, CPHI Milan CDMO https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/JustinWestendorf,Director-GlobalR&DatPhillipsMedisize20261002175110.png https://www.pharmanow.live/latest-news/adarx-pharmaceuticals-closes-602m-ipo-private-placement-sirna-pipeline 2026-10-02T18:45:52+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 Adarx Closes A $602.5M IPO And Private Placement For SiRNA Runway ADARx https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/adarx-pharmaceuticals-602m-ipo-private-placement-sirna-pipeline-202620261002184543.webp https://www.pharmanow.live/latest-news/greenwich-rx-recalls-compounded-glutathione-elevated-endotoxin-levels 2026-10-02T18:43:52+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 Greenwich Rx Recalls Glutathione Injections Over Endotoxin Levels Greenwich https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/greenwich-rx-compounded-glutathione-recall-elevated-endotoxin-levels-202620261002184142.webp https://www.pharmanow.live/latest-news/fda-launches-c3ti-demonstration-program-bayesian-pragmatic-trial-integration 2026-10-02T18:23:00+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 FDA Launches C3TI Program To Accelerate Pragmatic Trial Workflows FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-c3ti-demonstration-program-bayesian-pragmatic-trial-integration-202620261002182250.webp https://www.pharmanow.live/latest-news/fda-office-of-generic-drugs-leadership-divisional-structure-anda-filers 2026-10-02T10:38:37+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 OGD Publishes Full Leadership And Divisional Structures For ANDAs OGD https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/63943c32-40d2-4356-bdbe-3cffdfc97d87/502c6593-dd2d-449a-9eeb-45d000c53f66.png https://www.pharmanow.live/latest-news/fda-cder-rare-diseases-team-arc-program-orphan-drug-incentives 2026-10-02T17:57:29+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 FDA Outlines ARC Commitments And Orphan Drug Incentive Framework FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-cder-rare-diseases-team-arc-program-orphan-drug-incentives-202620261002174547.webp